Evidence mapPaperPMID 41709202Full record

ReviewJournal of nanobiotechnology2026

Artificial intelligence-driven nano-enhanced stem cell therapy for neurodegenerative diseases: from rational design to clinical translation.

Nan Chen, Shichan Wang, Jiyong Liu, Xiaoting Zheng, Huifang Shang

Abstract readReview
In one paragraph

Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nan ChenDepartment of Neurology, Laboratory of Neurodegenerative Disorders, Rare Disease Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
Shichan WangDepartment of Neurology, Laboratory of Neurodegenerative Disorders, Rare Disease Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
Jiyong LiuDepartment of Neurology, Laboratory of Neurodegenerative Disorders, Rare Disease Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
Xiaoting ZhengDepartment of Neurology, Laboratory of Neurodegenerative Disorders, Rare Disease Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
Huifang ShangDepartment of Neurology, Laboratory of Neurodegenerative Disorders, Rare Disease Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China. hfshang2002@126.com.

Funding

National Natural Science Foundation of China 82371430Sichuan Provincial Science and Technology Support Program 2022ZDZX0023
6 · The paper itself

Abstract

Neurodegenerative diseases (NDs) are progressive and incurable central nervous system disorders characterized by the accumulation of pathological proteins and the loss of neurons. Although stem cell transplantation offers a new treatment option, its clinical application is severely hindered due to imprecise delivery, low survival rate, and undirected differentiation. Many studies have used nanomaterials to enhance stem cell therapy. However, the rational design of these multifunctional nanomaterials often requires a large number of experiments and calculations to determine the optimal parameters. Meanwhile, the diagnosis of NDs and the design of nanomaterials are being profoundly influenced by artificial intelligence (AI) and data-driven modeling. Based on these advancements, we propose that AI can guide personalized nano-enhanced stem cell therapies. This review explores how machine learning (ML) and deep learning (DL) can address the current challenges in stem cell therapy and nano-enhanced stem cell therapies. More importantly, it provides a systematic framework for integrating AI across the entire nano-enhanced stem cell therapy. We analyzed how AI can optimize the design of nanobiological materials, thereby enhancing the survival rate of stem cells, targeted delivery, directing differentiation, and controlling the release of loaded drugs. Additionally, we proposed that AI can be used for post-transplant tracking and prognosis management. Beyond summarizing parallel advancements, this review proposes a closed-loop system that integrates patient-specific data, AI-driven design, and real-time monitoring, aiming to advance truly personalized medicine for NDs.

Indexed as

Artificial IntelligenceNanostructuresNeurodegenerative DiseasesStem Cell TransplantationAnimalsCell DifferentiationDeep LearningHumansMachine LearningStem CellsTranslational Research, BiomedicalArtificial intelligenceNanomaterialsNeurodegenerative diseasesStem cell transplantation

Identifiers

PMID41709202
PMCPMC13020350

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.